Repeated antitumour antibody therapy in man with suppression of the host response by cyclosporin A.
about
A phase-I study of repeated therapy with radiolabelled antibody to carcinoembryonic antigen using intermittent or continuous administration of cyclosporin A to suppress the immune response.Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab')2 antibodies.The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody.Unusual results from immunoassays and the role of the clinical endocrinologist.Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin.Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo.Tumour targeting of humanised cross-linked divalent-Fab' antibody fragments: a clinical phase I/II studyThe First Bagshawe lecture. Towards generating cytotoxic agents at cancer sitesPolyethylene glycol modification of a galactosylated streptavidin clearing agent: effects on immunogenicity and clearance of a biotinylated anti-tumour antibody.Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies?Review: advances in monoclonal antibody tumour targeting.A new application for liposomes in cancer therapy. Immunoliposomes bearing enzymes (immuno-enzymosomes) for site-specific activation of prodrugs.Clearance of circulating radio-antibodies using streptavidin or second antibodies in a xenograft model.Antibody distribution and dosimetry in patients receiving radiolabelled antibody therapy for colorectal cancer.Targeting enzymes for cancer therapy: old enzymes in new roles.Human anti-mouse antibody suppression with cyclosporin A.Anaphylactic reaction to radioimmunotherapy despite plasmapheresis to remove anti-mouse antibodies.Human immune response to monoclonal antibody-enzyme conjugates in ADEPT pilot clinical trial
P2860
Q33387699-D21AB551-BB81-42A4-A04D-A2BB72C3B435Q36079638-DEF61360-CF73-434C-9AB7-1A0839308855Q36080676-81C30B35-A777-4CA5-8C53-8272CDF73B44Q36399982-67291F36-0D0B-40BE-AB60-8093FC447EBBQ36443899-B23583CC-530F-4E5F-997B-33FC26C8C8C6Q37401525-7D7705C4-97B5-4ECB-8863-F59E69E9C3CAQ38283180-D27195DB-C626-4E41-956C-7096FDC86643Q38694283-19DECCAA-69F2-4062-B4EE-472122F2FC41Q39991117-932F2ED5-4BF0-410F-A06E-D7CC5DC5885EQ40672537-5CA6670F-3B2D-46F4-9A3B-F9D26B81A90AQ40694059-E2F9174A-5639-4820-8CF6-E98A5D9BBA86Q41507993-4EE1BE9A-0BAE-40FC-AC7E-8ADC0369D0D6Q41897782-A5E49770-19DF-4E17-BA3F-1A6EC9352FB4Q42172789-DF8A2C39-373A-40A0-A423-930D1910B395Q42590388-C244CECC-E5E5-407E-84DA-0050B987BEBBQ45091540-76EFB9F2-441F-4B1C-95A7-2DABA88C0BEDQ55379908-0D802626-2E96-451B-981A-DE379F57D138Q56574975-8DD8CC3F-4B74-4B2D-A142-DF7A12D838E7
P2860
Repeated antitumour antibody therapy in man with suppression of the host response by cyclosporin A.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年学术文章
@wuu
1988年学术文章
@zh-cn
1988年学术文章
@zh-hans
1988年学术文章
@zh-my
1988年学术文章
@zh-sg
1988年學術文章
@yue
1988年學術文章
@zh
1988年學術文章
@zh-hant
name
Repeated antitumour antibody t ...... ost response by cyclosporin A.
@ast
Repeated antitumour antibody t ...... ost response by cyclosporin A.
@en
type
label
Repeated antitumour antibody t ...... ost response by cyclosporin A.
@ast
Repeated antitumour antibody t ...... ost response by cyclosporin A.
@en
prefLabel
Repeated antitumour antibody t ...... ost response by cyclosporin A.
@ast
Repeated antitumour antibody t ...... ost response by cyclosporin A.
@en
P2093
P2860
P356
P1476
Repeated antitumour antibody t ...... ost response by cyclosporin A.
@en
P2093
Bagshawe KD
Ledermann JA
P2860
P2888
P304
P356
10.1038/BJC.1988.279
P407
P577
1988-11-01T00:00:00Z